These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 17912871)
41. Structure-based drug design and the discovery of aliskiren (Tekturna): perseverance and creativity to overcome a R&D pipeline challenge. Cohen NC Chem Biol Drug Des; 2007 Dec; 70(6):557-65. PubMed ID: 17999663 [TBL] [Abstract][Full Text] [Related]
42. [Is there a need for direct renin inhibitors?]. Grossman E Harefuah; 2008 Mar; 147(3):216-7, 278. PubMed ID: 18488862 [TBL] [Abstract][Full Text] [Related]
44. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Waldmeier F; Glaenzel U; Wirz B; Oberer L; Schmid D; Seiberling M; Valencia J; Riviere GJ; End P; Vaidyanathan S Drug Metab Dispos; 2007 Aug; 35(8):1418-28. PubMed ID: 17510248 [TBL] [Abstract][Full Text] [Related]
45. A new way to control blood pressure. Inactivating renin, which is made by the kidneys, may open the door to better blood pressure. Harv Heart Lett; 2007 May; 17(9):3. PubMed ID: 17517983 [No Abstract] [Full Text] [Related]
46. Aliskiren combined with losartan in diabetes and nephropathy. Kamoi K N Engl J Med; 2008 Sep; 359(10):1069; author reply 1069-70. PubMed ID: 18777611 [No Abstract] [Full Text] [Related]
47. Using plasma renin (PRA) testing to design follow-up drug treatment strategies in hypertensive patients already taking antirenin system drugs. Sealey JE; Laragh JH Am J Hypertens; 2009 Sep; 22(9):950. PubMed ID: 19701164 [No Abstract] [Full Text] [Related]
49. New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib. Hussar DA J Am Pharm Assoc (2003); 2007; 47(3):425-6, 428-30. PubMed ID: 17510042 [No Abstract] [Full Text] [Related]
50. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. Chrysant SG Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):305-14. PubMed ID: 18327992 [TBL] [Abstract][Full Text] [Related]
51. Aliskiren in type 2 diabetes and cardiorenal end points. Du X; Chen Z; Pan B N Engl J Med; 2013 Mar; 368(11):1065. PubMed ID: 23484841 [No Abstract] [Full Text] [Related]
52. Aliskiren in type 2 diabetes and cardiorenal end points. Onuigbo M; Onuigbo N N Engl J Med; 2013 Mar; 368(11):1064-5. PubMed ID: 23484840 [No Abstract] [Full Text] [Related]
53. Aliskiren in type 2 diabetes and cardiorenal end points. Pfeffer MA; Brenner BM; McMurray JJ N Engl J Med; 2013 Mar; 368(11):1065-6. PubMed ID: 23484839 [No Abstract] [Full Text] [Related]
54. Under pressure: future prospects in hypertension management. Interview by Laura Dormer. Brunner HR Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):921-3. PubMed ID: 18666842 [TBL] [Abstract][Full Text] [Related]
55. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651 [TBL] [Abstract][Full Text] [Related]
56. Aliskiren combined with losartan in diabetes and nephropathy. Panesar M; Damodar A N Engl J Med; 2008 Sep; 359(10):1068; author reply 1069-70. PubMed ID: 18768954 [No Abstract] [Full Text] [Related]
57. Aliskiren: a novel renin inhibitor for hypertension. Tayal V; Kalra BS Indian Heart J; 2008; 60(1):69-72. PubMed ID: 19212031 [TBL] [Abstract][Full Text] [Related]
59. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Campbell DJ Hypertension; 2008 Jan; 51(1):15-8. PubMed ID: 17984367 [No Abstract] [Full Text] [Related]
60. Aliskiren and its rapidly, evolving role in the management of cardio-thoracic diseases. Kapoor S Heart Lung Circ; 2009 Oct; 18(5):372. PubMed ID: 19084475 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]